-
SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF LATANOPROSTENE BUNOD INITIATORS AMONG MEDICARE FEE-FOR-SERVICE PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
Mar 18, 2026, 21:38 PM -
A QUALITATIVE STUDY TO EXPLORE PATIENT PERSPECTIVES ON FUTURE GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTROPHY (LGMD) SARCOGLYCANOPATHY SUBTYPES 2E/R4, 2D/R3, AND 2C/R5
Mar 18, 2026, 21:38 PM -
CONSENSUS ON BARRIERS AND UNMET NEEDS IN HEMOPHILIA CARE IN BRAZIL: A MODIFIED DELPHI STUDY
Mar 18, 2026, 21:38 PM -
ECONOMIC VALUE OF RSV MATERNAL VACCINATION TO PREVENT INFANT DISEASE IN ECUADOR
Mar 18, 2026, 21:38 PM -
GLOBAL REGULATORY ASYMMETRIES AND THE STRUCTURAL DRUG LAG: TIME TO MARKET AUTHORIZATION IN CÔTE D’IVOIRE
Mar 18, 2026, 21:38 PM -
HARNESSING AGENTIC AI FOR COHORT IDENTIFICATION: A CASE STUDY IN CLL/SLL PATIENTS TREATED WITH BTK INHIBITORS AT A US ACADEMIC HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
DOES ARTIFICIAL INTELLIGENCE IMPROVE OUTCOMES IN ACUTE ISCHEMIC STROKE CARE?
Mar 18, 2026, 21:38 PM -
REAL-WORLD EFFECTIVENESS OF DUPILUMAB IN REDUCING ORAL AND INHALED CORTICOSTEROID USE AMONG US PATIENTS WITH ASTHMA: ANALYSIS FROM THE HEALTHCARE INTEGRATED RESEARCH DATABASE
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS IN COMMERCIALLY INSURED PATIENTS WITH RECURRENT OR PROGRESSIVE ENDOMETRIAL CANCER (EC) IN THE USA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS WITH REAL-WORLD DATA REUSING BRAZILIAN HEALTH SYSTEM DATABASES: A CASE STUDY IN BREAST CANCER
Mar 18, 2026, 21:38 PM -
HEALTHCARE COST, RESOURCE USE, AND ECONOMIC MODELS OF CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER PATIENTS (MIBC)
Mar 18, 2026, 21:38 PM -
TRENDS IN THE USE OF REAL-WORLD EVIDENCE IN PRESS RELEASES ISSUED BY THE TOP 15 PHARMACEUTICAL COMPANIES
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT OF FINERENONE IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF):IMPLICATIONS FOR U.S. HEALTHCARE DECISION-MAKERS
Mar 18, 2026, 21:38 PM -
SURVIVING UNANCHORED INDIRECT COMPARISONS: AN EXTENSION OF MULTILEVEL UNANCHORED META-REGRESSION (ML-UMR) FOR SURVIVAL ANALYSES
Mar 18, 2026, 21:38 PM -
ARE EVIDENCE REVIEW REQUIREMENTS SIMILAR ACROSS HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES? A CROSS-SECTIONAL STUDY OF NICE, CDA, IQWIG AND EU JCA
Mar 18, 2026, 21:38 PM -
DO DATA SOURCES MATTER? COMPARING MARKET COST AND PAYER COST APPROACHES TO CALCULATING MEDICAL SPENDING MEASURES IN REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
PROBABILISTIC LINKING OF CLAIMS AND ELECTRONIC HEALTH RECORD (EHR) ENCOUNTERS USING THE FELLEGI-SUNTER STATISTICAL FRAMEWORK
Mar 18, 2026, 21:38 PM -
QUANTIFYING THE OPPORTUNITY: THE ECONOMIC AND COMMERCIAL CASE FOR ALS TREATMENT INNOVATION
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF A COMPOSITE ENDPOINT IN HYPOPHOSPHATASIA TO OPTIMIZE COST-EFFECTIVENESS DEMONSTRATION
Mar 18, 2026, 21:38 PM -
AFFORDABILITY OF PEDIATRIC DRUGS THROUGH CHINA’S NATIONAL DRUG PRICE NEGOTIATION: 2017-2024
Mar 18, 2026, 21:38 PM
